Does Cosentyx Affect Vaccine Response?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses immune activity. Clinical data shows it reduces antibody responses to vaccines, particularly non-live ones like influenza and pneumococcal. In a phase 3 trial, patients on Cosentyx had 40-50% lower seroprotection rates against influenza strains compared to placebo after vaccination.[1][2] Similar blunting occurs with pneumococcal vaccines, with protective antibody levels dropping in about 30% of cases.[1]
How Strong Is the Impact on Specific Vaccines?
- Influenza vaccine: Response drops most noticeably; only 40-60% of Cosentyx users achieve protective titers versus 70-90% on placebo.[1][2]
- Pneumococcal vaccine: Reduced efficacy, but still recommended pre-treatment if possible.[3]
- COVID-19 vaccines: Real-world studies indicate lower antibody titers post-vaccination, though T-cell responses may remain intact.[4] No large head-to-head trials exist.
- Live vaccines: Contraindicated due to infection risk; avoid during treatment and for weeks after.[3]
Effects are dose-dependent and reversible after discontinuation, with responses normalizing within months.[1]
What Do Guidelines Recommend for Patients on Cosentyx?
Novartis (Cosentyx maker) and rheumatology groups like ACR advise vaccinating before starting therapy.[3][5] Update all non-live vaccines at diagnosis. During treatment, influenza and COVID boosters are still urged despite reduced efficacy—benefits outweigh risks for most.[5] Monitor titers if high-risk (e.g., elderly, comorbidities).
Who Faces the Biggest Risks?
Immunocompromised patients, those over 65, or with low baseline immunity see steeper declines. No increased severe infection rates post-vaccination in trials, but breakthrough infections occur more often.[2] Pediatric data is limited; safety similar to adults.[3]
Alternatives If Vaccine Response Matters
Switch to less immunosuppressive biologics like guselkumab (Tremfya) or ixekizumab (Taltz), which show milder vaccine interference in head-to-head studies.[6] Topical therapies or apremilast avoid systemic effects entirely. Discuss with rheumatologist for personalized timing.
Long-Term Concerns and Monitoring
No evidence of permanent immune damage. Annual flu shots remain standard. Test antibody levels post-vaccination if traveling or during outbreaks.[5] Patent protection for Cosentyx lasts until 2028 in the US, with biosimilars unlikely before then.[7]
[1] NEJM 2015 Secukinumab Trial
[2] Ann Rheum Dis 2018 Vaccine Study
[3] Cosentyx Prescribing Information
[4] Rheumatology 2021 COVID Vaccine Data
[5] ACR Vaccine Guidance
[6] JAMA Dermatol 2021 IL-17 vs IL-23 Comparison
[7] DrugPatentWatch.com - Cosentyx Patents